Gryrotonic Training in Behcet-diseased Elders With Breast Cancer

November 5, 2026 updated by: Ali Mohamed Ali ismail, Cairo University

gryrotonic training may be a good exercise modality in Behcet-diseased elders with breast cancer

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

forty Behcet-diseased elders with breast cancer will randomy divide into group I (receive gyrotonic exercise three session weekly for 12 week) or group II (wait list)

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Egypt
    • Dokki
      • Giza, Dokki, Egypt
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

65 years to 75 years (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • beast cancer survivors
  • behcet diseas patients

Exclusion Criteria:

  • cardiac or repiratory or renal failure patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: group number 1

twenty Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will 45 min
Behavioral: exercise

twnety Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will last for 45 min
No Intervention: group number 2

twenty Behcet-diseased elders who survivied from breast cancer will be wait list for 12 weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Short Physical Performance Battery
Time Frame: it will be measured after 12 weeks

the total score will be calcualted
it will be measured after 12 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dual task gait speed
Time Frame: It will be measured after 12 weeks

this task assess gait speed
It will be measured after 12 weeks
Four-square step test
Time Frame: It will be measured after 12 weeks

it is fucntional balnce test
It will be measured after 12 weeks
grip strenghts
Time Frame: It will be measured after 12 weeks

it is a measure of grip strenghths in dominant hand
It will be measured after 12 weeks
time up- and go testing
Time Frame: It will be measured after 12 weeks

it is a measure of fall risk
It will be measured after 12 weeks
sit-to-stand 30-second testing
Time Frame: It will be measured after 12 weeks

asess number of repteations of sit-to-staning in 30 seconds
It will be measured after 12 weeks
six minute walking testingg
Time Frame: It will be measured after 12 weeks

distance covered by subject in six minutes wil be assessed
It will be measured after 12 weeks
10-meters walking testing
Time Frame: It will be measured after 12 weeks

time covered for walking for ten meter will be assessed
It will be measured after 12 weeks
trunk-flexor McGill core endurance test
Time Frame: It will be measured after 12 weeks

this test will assess endurance of trunk flexors
It will be measured after 12 weeks
trunk-extensor McGill core endurance test
Time Frame: It will be measured after 12 weeks

this test will assess endurance of trunk extensors
It will be measured after 12 weeks
right-lateral-trunk-bending McGill core endurance test
Time Frame: It will be measured after 12 weeks

this test will assess endurance of right lateral trunk bendors
It will be measured after 12 weeks
left-lateral-trunk-bending McGill core endurance test
Time Frame: It will be measured after 12 weeks

this test will assess endurance of left lateral trunk bendors
It will be measured after 12 weeks
arm flexion in thrity seconds
Time Frame: It will be measured after 12 weeks

it will assess numbers (repeations) of arm flexion in thirty second
It will be measured after 12 weeks
maximal nubmer of push up
Time Frame: It will be measured after 12 weeks

this will assess maximal number of performed psh ups in speciifc time
It will be measured after 12 weeks
behcet disease quality of life
Time Frame: It will be measured after 12 weeks

questioanire that will assess life quality in behcet disease (total score will be estiamted)
It will be measured after 12 weeks
total score of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess quality of life
It will be measured after 12 weeks
physical fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess physical fucntion related quality of life
It will be measured after 12 weeks
role fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess role fucntion related quality of life
It will be measured after 12 weeks
emotional fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess emotional fucntion related quality of life
It will be measured after 12 weeks
cognitive fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess cognitive fucntion related quality of life
It will be measured after 12 weeks
social fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess social fucntion related quality of life
It will be measured after 12 weeks
fatigue fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess fatigue
It will be measured after 12 weeks
nausea-vomiting subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it is a questioaire asess nausea-vomiting
It will be measured after 12 weeks
pain subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess pain
It will be measured after 12 weeks
dyspnea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess dyspnea
It will be measured after 12 weeks
insomnia subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess insomnia
It will be measured after 12 weeks
appetite-loss subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess appetite loss
It will be measured after 12 weeks
constipation subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess constipation
It will be measured after 12 weeks
diarrhea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess diarrhea
It will be measured after 12 weeks
financial difficulties subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time Frame: It will be measured after 12 weeks

it will assess financial difficulties
It will be measured after 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ali MA Ismail, phd, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 30, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 5, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 10, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB00014233-118

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings